| Development of PI3K inhibitors: lessons learned from early clinical trials J Rodon, R Dienstmann, V Serra, J Tabernero Nature reviews Clinical oncology 10 (3), 143-153, 2013 | 861 | 2013 |
| Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors JC Bendell, J Rodon, HA Burris, M de Jonge, J Verweij, D Birle, ... J Clin Oncol 30 (3), 282-290, 2012 | 783 | 2012 |
| Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 761 | 2019 |
| Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma L De Mattos-Arruda, R Mayor, CKY Ng, B Weigelt, F Martínez-Ricarte, ... Nature communications 6 (1), 8839, 2015 | 745 | 2015 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 690 | 2018 |
| TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma J Anido, A Sáez-Borderías, A Gonzàlez-Juncà, L Rodón, G Folch, ... Cancer cell 18 (6), 655-668, 2010 | 676 | 2010 |
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ... Cancer discovery 2 (11), 1036-1047, 2012 | 594 | 2012 |
| Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors R Dienstmann, J Rodon, V Serra, J Tabernero Molecular cancer therapeutics 13 (5), 1021-1031, 2014 | 523 | 2014 |
| Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations D Tamborero, C Rubio-Perez, J Deu-Pons, MP Schroeder, A Vivancos, ... Genome medicine 10, 1-8, 2018 | 476 | 2018 |
| Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations D Tamborero, C Rubio-Perez, J Deu-Pons, MP Schroeder, A Vivancos, ... Genome medicine 10, 1-8, 2018 | 474 | 2018 |
| Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial J Rodon, JC Soria, R Berger, WH Miller, E Rubin, A Kugel, A Tsimberidou, ... Nature medicine 25 (5), 751-758, 2019 | 444 | 2019 |
| Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 AW Tolcher, J Sarantopoulos, A Patnaik, K Papadopoulos, CC Lin, ... Journal of Clinical Oncology 27 (34), 5800-5807, 2009 | 412 | 2009 |
| Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors R Dienstmann, J Rodon, A Prat, J Perez-Garcia, B Adamo, E Felip, ... Annals of oncology 25 (3), 552-563, 2014 | 404 | 2014 |
| Phase I dose-escalation study of JNJ-42756493, an oral pan–Fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors J Tabernero, R Bahleda, R Dienstmann, JR Infante, A Mita, A Italiano, ... Journal of Clinical Oncology 33 (30), 3401-3408, 2015 | 397 | 2015 |
| Phosphatidylinositol 3-kinase α–selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study D Juric, J Rodon, J Tabernero, F Janku, HA Burris, JHM Schellens, ... Journal of Clinical Oncology 36 (13), 1291, 2018 | 369 | 2018 |
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 352 | 2015 |
| mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ... Science translational medicine 5 (196), 196ra99-196ra99, 2013 | 314 | 2013 |
| AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas M Elkabets, E Pazarentzos, D Juric, Q Sheng, RA Pelossof, S Brook, ... Cancer cell 27 (4), 533-546, 2015 | 310 | 2015 |
| BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study T Kaley, M Touat, V Subbiah, A Hollebecque, J Rodon, AC Lockhart, ... Journal of Clinical Oncology 36 (35), 3477, 2018 | 298 | 2018 |
| Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer F Meric-Bernstam, AM Johnson, EEI Dumbrava, K Raghav, K Balaji, ... Clinical Cancer Research 25 (7), 2033-2041, 2019 | 279 | 2019 |
